Accelerating therapeutic antibody discovery to eradicate cancer

The ALADDIN project streamlines the process for an improved treatment of disease

An integrated platform for discovering therapeutic antibodies 

We upgrade the current state-of-the-art techniques

Therapeutic antibodies (Abs) have shown to be efficient in the diagnosis and treatment of cancer. The ALADDIN research project combines various technologies related to the generation and identification of Abs into one single platform. This will significantly enhance the process, making it faster and more cost-effective than current solutions.

Joining forces for a common goal

 Complementary skills from Europe and beyond

The ALADDIN consortium is formed by eight partners: research institutions, universities, and SMEs. The expertise of our team ranges from synthetic and molecular biology to mathematical modelling and microfluidics, ensuring a multidisciplinary approach for reaching our objectives.

The latest news from ALADDIN

Stay up-to-date on our progress

Find out more about the work conducted in the ALADDIN project in our news and blog articles.

This project has received funding from the EIC Pathfinder programme 2023 of the European Innovation Council (EIC) under Grant Agreement#101130574. This result only reflects the author’s view, and the EU is not responsible for any use that may be made of the information it contains.

©2024 copyright ALADDIN Consortium members. Confidential. All rights reserved.